Predict responders and non-responders from pre-infusion CAR-T product
As published in the journal “Blood”, researchers used the IsoPlexis system to stratify patient responders and non-responders to CAR-T therapy in Non-Hodgkins lymphoma, directly from the pre-infusion product, using IsoPlexis’ unique Polyfunctional Strength Index (PSI). Key findings:
- Preinfusion CAR product T-cell subsets with a high polyfunctional profile, i.e. large degree of single-cell cytokine potency, associates significantly with clinical outcome
- Existing technologies used traditionally for potency were unable to detect these associations in the CAR-T product, in a side by side study
- PSI of the product was associated with the Objective Response, highlighting the ability to use such metrics in a variety of contexts for optimizing Cell Therapy development
Citation: Rossi J, et al. Blood. 2018.
GET THE FULL DATA